ReviewDigestive diseases and sciences2024
Impact of Obesity and Metabolic Syndrome on IBD Outcomes.
Review in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial.BMC gastroenterology · 2025Trial
- Treatable traits in inflammatory bowel disease: a conceptual framework for personalized care.EClinicalMedicine · 2026Review
- Rising Burden and Clinical Impact of Metabolic Syndrome in Inflammatory Bowel Disease: A Real-World Cohort Study.United European gastroenterology journal · 2026Article
- Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.Current diabetes reports · 2026Review
- Article
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- SR9009 regulates macrophage polarization via the NR1D1/NF-κB axis to ameliorate obesity-associated ulcerative colitis.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): Consensus on Obesity and Cardiometabolic Comorbidities in Inflammatory Bowel Disease using Evidence Synthesis and the RAND/UCLA Appropriateness Method.medRxiv : the preprint server for health sciences · 2025Article
- Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2025Article
- Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.Journal of Crohn's & colitis · 2025Review
- Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications.Biomolecules · 2025Review
- The circadian clock, metabolism, and inflammation-the holy trinity of inflammatory bowel diseases.Clinical science (London, England : 1979) · 2025Review
- Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.Current issues in molecular biology · 2025Review
- Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.Advances in therapy · 2025Review
- Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan.Journal of inflammation research · 2025Article
- The Impact of Obesity-Related Complications on Healthcare Costs - Outcomes of a Pharmacoeconomic Weight Loss Model.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Evaluating the triglyceride-glucose index as a biomarker for inflammatory bowel disease risk: insights from a UK Biobank prospective study.Frontiers in immunology · 2025Article
- Exploring the Shared Diagnostic Genes in IBD and Psoriasis through Bioinformatics and Experimental Assays.International journal of medical sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe recent surge in inflammatory bowel disease (IBD) cases has paralleled a significant rise in obesity and metabolic comorbidities rates. In this article, we explore the potential influence of obesity and associated metabolic comorbidities on disease progression, complications, treatment response, surgical outcomes, health economics, and the potential impact of obesity treatment on the course of IBD.
findingsContrary to visceral adiposity, obesity does not consistently result in an increased risk of IBD-related complications. Patients with IBD have a higher risk of acute arterial events, likely linked to systemic inflammation. Substantial evidence suggests that obesity has a negative impact on the response to IBD treatment, with this effect being most thoroughly studied in biologics and immunomodulators. The rates of overall complications and post-operative infections are higher in patients who are obese. There are limited but promising data regarding the impact of weight loss techniques, including exercise, medications, and bariatric interventions, on the outcomes in IBD. Both obesity and diabetes have adverse effects on the overall quality of life and place an increased financial burden on the IBD population. A growing body of evidence indicates a connection between obesity and associated metabolic comorbidities and negative outcomes in IBD, yet further efforts are required to fully understand this relationship.
Indexed as
Identifiers
38864929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.